(2R)-2-{2-[(1R)-1-(4-Chlorophenyl)-1-Phenylethoxy]Ethyl}-1-Methylpyrrolidine (2E)-But-2-Enedioate

In pharmaceutical solid-state engineering, the chemical entity designated (2R)-2-{2-[(1R)-1-(4-Chlorophenyl)-1-Phenylethoxy]Ethyl}-1-Methylpyrrolidine (2E)-But-2-Enedioate (CAS 14976-57-9) crystallizes as the mono‑fumarate salt of an enantiopure benzhydryl ether‑pyrrolidine. The single R,R configuration at the two chiral centers is a prerequisite for H₁ receptor antagonism; the bulk substance is routinely controlled for enantiomeric purity via chiral HPLC (typical limit: <0.3% of the S,S isomer). The molecular formula C₂₁H₂₆ClNO·C₄H₄O₄ yields a relative molecular mass of 459.96 g mol⁻¹. In this salt the fumarate dianion bridges two protonated pyrrolidine nitrogens, producing a 1:1 stoichiometry that raises the melting point to 177–180 °C (with decomposition) and restricts aqueous solubility at pH 6.8 to approximately 0.1 mg mL⁻¹. This physicochemical profile couples low dose strength (1.34 mg fumarate equivalent to 1 mg base) with moderate hygroscopicity and creates distinct challenges in oral solid dosage form manufacture when compared with other first‑generation antihistamines.

What Limits the Shelf-Life of Clemastine Fumarate Tablets under ICH Zone IVb Conditions?

Forced degradation data indicate that the primary vulnerability is oxidative N‑demethylation at the pyrrolidine ring, accelerated by trace peroxides in excipients such as povidone or crospovidone. When tablets containing 1.0 mg clemastine base were stored at 40 °C/75% RH in HDPE bottles without desiccant, the major degradation product co‑eluted with the pharmacopoeial specified impurity Clemastine Related Compound A (the N‑oxide derivative) and exceeded the 0.5% threshold within three months. In contrast, foil‑blister packaging with a PVdC barrier maintained the impurity level below 0.2% over 24 months. This stability dichotomy has driven the industry toward the selection of low‑peroxide excipient grades: microcrystalline cellulose complying with peroxide specification <50 ppm (determined by the iodometric method per Ph. Eur. 2.5.5) and the elimination of polyethylene glycol from film‑coating formulations. Concurrently, vigilance over the fumarate counter‑ion is required because dissociation in high‑pH microenvironments can liberate fumaric acid, which sublimes above 200 °C and, during accelerated testing at 60 °C, deposits on closure liners, artificially reducing the assay by up to 2% through mass‑balance loss rather than true active degradation.

Wet Granulation Endpoint Control in High-Shear Mixers Processing 0.5% Drug Load Formulations

Direct compression of clemastine fumarate at 0.5–1.5% drug load regularly fails content uniformity tests (USP <905>) because of electrostatic adhesion of micronized drug particles to metal contact surfaces. Aqueous wet granulation using a 25 L high‑shear mixer‑granulator (Gral 10, impeller speed 300 rpm, chopper 1500 rpm) resolves this segregation, but the processing window is narrow: the addition of 8–10% (w/w) purified water over 120 s yields granules with a mean particle size D₅₀ of 120–180 µm, adequate for tablet compression at 8–12 kN on a 16‑station rotary press. If water quantity exceeds 11%, local overwetting precipitates an over‑granulated fraction >500 µm that resists drying and retains residual moisture above 2.5% after fluid‑bed drying at 60 °C inlet air. That residual water plasticizes the fumarate salt, leading to punch‑filming and capping during compression at even moderate speeds (40 rpm). The endpoint is monitored in real time by power consumption integration; a relative standard deviation of impeller power draw below 5% over the final 30 s of wet massing correlates with blend uniformity RSD <3% (n=10). Magnesium stearate is added at 0.5% and blended for 3 min; longer mixing significantly reduces tensile strength because the fumarate salt abrades the lubricant, generating a hydrophobic film on the granule surface. When post‑compression disintegration times drift beyond 15 min (as per Ph. Eur. 2.9.1), the root cause is often intragranular over‑compaction rather than lubricant excess. The hardness‑disintegration relationship for clemastine fumarate tablets shows a steep inflection point at 6–7 kp; increasing hardness to 8 kp extends disintegration to 22 min and suppresses dissolution below 75% at 45 min in 0.1 N HCl. This behavior differs notably from that of diphenhydramine hydrochloride tablets, which maintain rapid disintegration up to 12 kp owing to the hydrochloride salt’s higher aqueous solubility.

Comparative Binding Affinity and Therapeutic Distinction from Second‑Generation Agents

In radioligand displacement assays using human recombinant H₁ receptors expressed in CHO cells, clemastine exhibits a Kᵢ of 0.05–0.1 nM, classifying it among the highest‑affinity first‑generation antihistamines. The sedative liability arises not from H₁ affinity per se but from a brain:plasma concentration ratio exceeding 1.5 attributable to the free base’s log P of 5.2 and a pKₐ of 9.2 that ensures passive diffusion across the blood‑brain barrier at physiological pH. This contrasts with second‑generation agents such as cetirizine (log D₇.₄ 1.5, substrate for P‑glycoprotein efflux) and fexofenadine (log P 2.8, additionally zwitterionic at plasma pH). The anticholinergic profile of clemastine, measured as pA₂ for muscarinic M₁ receptors, is 8.0, roughly 10‑fold higher than that of loratadine but 5‑fold lower than that of diphenhydramine. This differential translates clinically: at a standard dose of 1 mg twice daily, the incidence of dry mouth is reported in 5–10% of patients, compared with 20–30% for diphenhydramine 50 mg.

Comparative Sedation and Receptor Affinity in Selected Antihistamines

Agent	H₁ Kᵢ (nM)	M₁ pA₂	Mean Sedation Score (VAS 0–100 mm)	Plasma Half‑Life (h)
Clemastine fumarate	0.08	8.0	22	21
Diphenhydramine HCl	1.0	8.8	34	9
Cetirizine 2HCl	6.0	<5.0	8	8
Fexofenadine HCl	175	<5.0	4	14

Intra‑class distinctions become critical when selecting a first‑generation antihistamine for nocturnal pruritus where moderate sedation is desired but excessive anticholinergic burden must be avoided. Clemastine fumarate occupies an intermediate position: its sedation latency of 1.5–2 h post‑dose aligns with sleep architecture, whereas diphenhydramine’s faster onset (30–60 min) and shorter half‑life produce a mid‑sleep trough that can precipitate early waking. When manufacturing high‑dose chewable tablets aimed at paediatric populations, substitution of clemastine fumarate with another salt is not straightforward because the fumarate form masks the bitter taste of the amine more effectively than the hydrochloride form due to its lower aqueous solubility at salivary pH. This taste‑masking effect, however, vanishes if the tablet disintegrates in the oral cavity before swallowing; hence, the fumarate salt is often marketed as a swallow tablet or syrup rather than a chewable.

If the Fumarate Counterion Drives Hygroscopicity, Pre‑Drying Becomes Mandatory

Dynamic vapor sorption data on pure clemastine fumarate at 25 °C show a mass increase of 0.8% at 60% RH and 2.5% at 75% RH, confirming that the critical relative humidity for deliquescence is not reached but enough surface water is adsorbed to bridge particles during compression. On a 10‑station instrumented rotary press running at 60 rpm, the ejection force rose from 120 N to 210 N when blends were conditioned at 65% RH for 4 h prior to compression; the corresponding tablet friability increased from 0.3% to 2.8% (Ph. Eur. 2.9.7). To maintain manufacturing reliability, in‑process environmental controls specifying relative humidity <40% and dew point <8 °C are enforced during blending and compression. Excipients such as mannitol (Pearlitol 200SD) are pre‑dried at 50 °C for 2 h in a fluid‑bed dryer to a loss‑on‑drying value <0.2%. These constraints are stricter than those typically applied to cetirizine dihydrochloride formulations, where excipient pre‑drying is unnecessary at ambient humidity up to 55% RH.

Pharmacopoeial Specification Summary for Clemastine Fumarate API (USP vs Ph. Eur.)

Attribute	USP Monograph	Ph. Eur. Monograph
Assay (anhydrous basis)	98.0–102.0% by HPLC	99.0–101.0% by potentiometric titration
Enantiomeric purity	Not specified	≥99.0% (R,R) enantiomer
Related substances	Any individual impurity ≤0.5%; total ≤1.0%	Impurity A ≤0.3%; unspecified impurities ≤0.10%; total ≤0.5%
Water (Karl Fischer)	≤0.5%	≤0.5%
Residue on ignition	≤0.1%	≤0.1%
Heavy metals	≤10 ppm	≤10 ppm

When clemastine fumarate is formulated with artificial sweeteners such as sodium saccharin in syrup vehicles, the high pH of the saccharinate anion (pH 8.5 in water) can deprotonate the pyrrolidine nitrogen and liberate free base, which has an aqueous solubility of <0.01 mg mL⁻¹ and precipitates as a white film on container walls. Citrate buffer (10 mM, pH 5.0) is therefore included in syrup preparations to suppress this incompatibility. No equivalent precipitation is observed with diphenhydramine hydrochloride syrups because the hydrochloride salt displays solubility in excess of 500 mg mL⁻¹ and remains fully ionized across a broad pH range. In the context of emerging formulations exploring sublingual delivery, the fumarate salt’s moderate solubility coupled with its rapid first‑pass metabolism (hepatic CYP2D6 and CYP3A4 yielding 80% oral clearance) means that a higher buccal dose would be required to achieve the same systemic exposure. Early feasibility work on orally disintegrating films (ODFs) loaded with clemastine fumarate at 0.5 mg cm⁻² encountered drug recrystallization during drying; this was mitigated by the incorporation of 5% (w/w of polymer) citric acid that maintains the drug in its protonated form. Such formulation differentiation is unnecessary for the inherently water‑soluble second‑generation antihistamines, highlighting how salt selection directly governs the range of viable dosage forms beyond traditional tablets and syrups.